RNLX

Renalytix Plc (RNLX) | Rumor.io

Renalytix

RNLX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about RNLX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 30

Renalytix Plc ($RNLX) is expected to report poor earnings, with some investors questioning the company's execution and potential for dilution.
The company's management has committed to buying around 245k shares in the new round of funding, which some investors see as a positive sign.
Despite the challenges, some investors believe $RNLX could set up nicely in 3-6 months, with a potential rebound in the stock price.

Generated by AI

Sentiment

Of the messages about RNLX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.13% -14.58
Bearish	—	—	—	21.88% +14.58

Bullish· Jul 31

$RNLX is expected to break through the $0.50 mark, potentially leading to a significant price increase.
The company is well-positioned to capitalize on a large market, with a potential revenue stream of $995 per kit and a target market of 14 million.
A slow and steady uptrend in the stock price is a clear sign of a sustainable price increase, with a potential buyout opportunity at 2x-3x the current price after a certain price point is reached.

Bearish· Jul 11

The stock has been subject to significant price declines, with some users suggesting it could drop to $0.00.
The company's recent news, including the NASDAQ delisting, has negatively impacted the stock.
The stock's price action has been characterized as a "pump and dump" and some users are speculating that the company may be selling shares into the market, potentially leading to further declines.

Generated by AI

Topics

Of the messages about RNLX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	94.29%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	5.71%

Announcements· Mar 4

Renalytix Plc received an unsolicited acquisition approach from a large, well-capitalized public diagnostics company, prompting the company to initiate a formal sale process.
The company's FDA-approved kidneyintelX.dkd test has been added to the US Government's 10-year Acquisition Contract for early kidney disease testing, with a set price of $950 per result, and is also being reviewed for Medicare coverage.
Renalytix has $2.3M in cash, $1.4M in securities, and is in financing talks with shareholders and new investors, as it considers all options following the unsolicited acquisition offer.

Technical Analysis· Feb 12

$RNLX has broken out, with a strong move upwards, and is expected to continue.
The 200 EMA is acting as support on the 1-minute chart, and a break above $1.50 is a potential target.
All technical indicators are in place for a massive move upwards, with a cup and handle formation on the daily chart and a strong bounce expected.

Generated by AI

Community

Of the messages about RNLX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	62.15%
Newcomers	—	—	—	37.85%

Regulars· Mar 4

Renalytix Plc has received an unsolicited approach from a possible strategic acquirer, has launched a formal sale process, and is providing an update on its financing.
$RNLX is showing high relative strength and is worth keeping on the radar for potential further gains.
$RNLX is trending over its EMAs, with a 25.7% gain already, but may be due for a drop; its float is 46.3M and short interest is 2.7%.

Newcomers· Mar 4

The newcomer is excited about the stock's price increase, mentioning a 1.44 squeeze pre-market.
The asset's revenue from AstraZeneca's Farxiga medication has increased by 39% to $5.96 billion in 2023.
The newcomer believes the takeover of the company is likely, which has led to a significant price increase, potentially exceeding 400%.

Generated by AI

Also Discussed

Investors talking about RNLX also mention

#	Name	Attention
1	Intelligent Bio Solutions Inc.INBS	0%0
2	Ainos, Inc.AIMD	0%+0
3	AFIB - Acutus Medical, Inc.	——
4	Beamr Imaging Ltd. Ordinary ShareBMR	0%0
5	Arisz Acquisition Corp.ARIZ	0%+0
6	Amprius Technologies Inc.AMPX	0.01%-0.07
7	Annexon Inc.ANNX	0%+0
8	Nkgen Biotech Inc.NKGN	0%0
9	Kazia Therapeutics Ltd Sponsored ADRKZIA	0%new
10	MHUA - Meihua International Medical Technologies Co., Ltd.	——

Renalytix Plc

Location

Social

What share of all stock conversation is about RNLX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 30

Renalytix Plc ($RNLX) is expected to report poor earnings, with some investors questioning the company's execution and potential for dilution.
The company's management has committed to buying around 245k shares in the new round of funding, which some investors see as a positive sign.
Despite the challenges, some investors believe $RNLX could set up nicely in 3-6 months, with a potential rebound in the stock price.

Generated by AI

Sentiment

Of the messages about RNLX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.13% -14.58
Bearish	—	—	—	21.88% +14.58

Bullish· Jul 31

$RNLX is expected to break through the $0.50 mark, potentially leading to a significant price increase.
The company is well-positioned to capitalize on a large market, with a potential revenue stream of $995 per kit and a target market of 14 million.
A slow and steady uptrend in the stock price is a clear sign of a sustainable price increase, with a potential buyout opportunity at 2x-3x the current price after a certain price point is reached.

Bearish· Jul 11

The stock has been subject to significant price declines, with some users suggesting it could drop to $0.00.
The company's recent news, including the NASDAQ delisting, has negatively impacted the stock.
The stock's price action has been characterized as a "pump and dump" and some users are speculating that the company may be selling shares into the market, potentially leading to further declines.

Generated by AI

Topics

Of the messages about RNLX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	94.29%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	5.71%

Announcements· Mar 4

Renalytix Plc received an unsolicited acquisition approach from a large, well-capitalized public diagnostics company, prompting the company to initiate a formal sale process.
The company's FDA-approved kidneyintelX.dkd test has been added to the US Government's 10-year Acquisition Contract for early kidney disease testing, with a set price of $950 per result, and is also being reviewed for Medicare coverage.
Renalytix has $2.3M in cash, $1.4M in securities, and is in financing talks with shareholders and new investors, as it considers all options following the unsolicited acquisition offer.

Technical Analysis· Feb 12

$RNLX has broken out, with a strong move upwards, and is expected to continue.
The 200 EMA is acting as support on the 1-minute chart, and a break above $1.50 is a potential target.
All technical indicators are in place for a massive move upwards, with a cup and handle formation on the daily chart and a strong bounce expected.

Generated by AI

Community

Of the messages about RNLX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	62.15%
Newcomers	—	—	—	37.85%

Regulars· Mar 4

Renalytix Plc has received an unsolicited approach from a possible strategic acquirer, has launched a formal sale process, and is providing an update on its financing.
$RNLX is showing high relative strength and is worth keeping on the radar for potential further gains.
$RNLX is trending over its EMAs, with a 25.7% gain already, but may be due for a drop; its float is 46.3M and short interest is 2.7%.

Newcomers· Mar 4

The newcomer is excited about the stock's price increase, mentioning a 1.44 squeeze pre-market.
The asset's revenue from AstraZeneca's Farxiga medication has increased by 39% to $5.96 billion in 2023.
The newcomer believes the takeover of the company is likely, which has led to a significant price increase, potentially exceeding 400%.

Generated by AI

Renalytix

Social

Sep 30

Sentiment

Bullish· Jul 31

Bearish· Jul 11

Topics

Announcements· Mar 4

Technical Analysis· Feb 12

Community

Regulars· Mar 4

Newcomers· Mar 4

Also Discussed

Renalytix Plc

Company Information

Location

Also Discussed

Social

Sep 30

Sentiment

Bullish· Jul 31

Bearish· Jul 11

Topics

Announcements· Mar 4

Technical Analysis· Feb 12

Community

Regulars· Mar 4

Newcomers· Mar 4